A study to investigate how the drug AZD7594 is absorbed in the blood stream, how safe and tolerable it is when administered by DPI once daily via inhalation over two weeks of treatment in adolescent patients with asthma. - Trial 2019-001259-37
Access comprehensive clinical trial information for 2019-001259-37 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca AB and is currently status unknown. The study focuses on Asthma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2019-001259-37
Trial Details
EU Clinical Trials Register • 2019-001259-37
A study to investigate how the drug AZD7594 is absorbed in the blood stream, how safe and tolerable it is when administered by DPI once daily via inhalation over two weeks of treatment in adolescent patients with asthma.
Study Focus
Sponsor & Location
AstraZeneca AB
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
To assess the PK profile of AZD7594 at steady state following daily inhalations for 2 weeks
ICD-10 Classifications
Asthma
Asthma, unspecified
Nonallergic asthma
Mixed asthma
Predominantly allergic asthma
Data Source
EU Clinical Trials Register
2019-001259-37
Non-Device Trial